Sanofi (NASDAQ:SNY) Shares Acquired by Old Port Advisors

Old Port Advisors grew its position in Sanofi (NASDAQ:SNY – Get Rating) by 6.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,975 shares of the company’s stock after buying an additional 1,736 shares during the quarter. Old Port Advisors’ holdings in Sanofi were worth $1,403,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of SNY. Assetmark Inc. boosted its holdings in Sanofi by 55.1% in the third quarter. Assetmark Inc. now owns 57,990 shares of the company’s stock valued at $2,205,000 after purchasing an additional 20,596 shares during the period. Colony Group LLC boosted its holdings in Sanofi by 39.5% in the third quarter. Colony Group LLC now owns 23,551 shares of the company’s stock valued at $895,000 after purchasing an additional 6,668 shares during the period. Greenleaf Trust boosted its holdings in Sanofi by 8.2% in the second quarter. Greenleaf Trust now owns 11,232 shares of the company’s stock valued at $562,000 after purchasing an additional 848 shares during the period. Rockefeller Capital Management L.P. boosted its holdings in Sanofi by 4.8% in the third quarter. Rockefeller Capital Management L.P. now owns 193,940 shares of the company’s stock valued at $7,372,000 after purchasing an additional 8,946 shares during the period. Finally, SG Americas Securities LLC boosted its holdings in Sanofi by 250.9% in the third quarter. SG Americas Securities LLC now owns 72,164 shares of the company’s stock valued at $2,744,000 after purchasing an additional 51,598 shares during the period. 10.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SNY has been the subject of a number of recent research reports. The Goldman Sachs Group initiated coverage on Sanofi in a report on Friday, December 16th. They issued a “buy” rating for the company. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a report on Friday, December 2nd. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Sanofi in a report on Tuesday, December 13th. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and an average target price of $102.88.

Sanofi Stock Down 0.8 %

SNY opened at $47.74 on Friday. The business’s 50-day simple moving average is $47.98 and its 200-day simple moving average is $45.01. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.05 and a current ratio of 1.42. Sanofi has a one year low of $36.91 and a one year high of $58.10. The stock has a market capitalization of $120.38 billion, a P/E ratio of 16.87, a price-to-earnings-growth ratio of 1.48 and a beta of 0.54.

Sanofi (NASDAQ:SNY – Get Rating) last posted its earnings results on Friday, February 3rd. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The firm had revenue of $10.95 billion for the quarter, compared to analyst estimates of $11.51 billion. Sanofi had a return on equity of 28.00% and a net margin of 15.70%. Analysts anticipate that Sanofi will post 4.4 EPS for the current year.

Sanofi Cuts Dividend

The business also recently declared an annual dividend, which will be paid on Friday, June 23rd. Investors of record on Wednesday, May 31st will be given a $1.377 dividend. This represents a yield of 2.94%. The ex-dividend date of this dividend is Tuesday, May 30th. Sanofi’s dividend payout ratio (DPR) is presently 44.52%.

About Sanofi

(Get Rating)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.